ライフサイエンスコーパス: beta2 adrenergic receptor

1 aits via binding to various receptors (e.g., beta2-adrenergic receptor).

2 us positions in purified preparations of the beta2 adrenergic receptor.

3 and the modulation of these channels by the beta2 adrenergic receptor.

4 bserved in Galphas upon binding of Gs to the beta2 adrenergic receptor.

5 ion of both the transferrin receptor and the beta2 adrenergic receptor.

6 prototypical recycling membrane protein, the beta2-adrenergic receptor.

7 lin, and PDE4D (phosphodiesterase 4D) to the beta2-adrenergic receptor.

8 tions of the potential energy surface of the beta2-adrenergic receptor.

9 rnalization of a set of mutants of the human beta2-adrenergic receptor.

10 or the activation of the MAPK pathway by the beta2-adrenergic receptor.

11 ne (Gly/Gly), at aminoacid residue 16 of the beta2-adrenergic receptor.

12 e Arg16Gly and Gln27Glu polymorphisms of the beta2-adrenergic receptor.

13 5 and TM6), similar to that observed for the beta2-adrenergic receptor.

14 to recruit the ubiquitin ligase Nedd4 to the beta2-adrenergic receptor.

15 nophosphate phosphodiesterases to Gs-coupled beta2-adrenergic receptors.

16 bligate for resensitization and recycling of beta2-adrenergic receptors.

17 of terbutaline is mediated by activation of beta2-adrenergic receptors.

18 Pharmacologic inhibition of beta2-adrenergic receptor 2 and protein kinase A, as wel

19 Subsequently, we identified the beta2 adrenergic receptor (ADRB2) as a downstream target

20 Polymorphisms in the beta2 adrenergic receptor (ADRB2), in particular G16R, Q

21 re prevented by treatment with the selective beta2-adrenergic receptor (ADRB2) antagonist ICI118,551

22 previous study, the Gly16Arg genotype of the beta2-adrenergic receptor (ADRB2) gene did not influence

23 with reduced expression of the gene for the beta2-adrenergic receptor (ADRB2) in CD4(+) lymphocytes

24 mozygous for arginine at aminoacid 16 of the beta2-adrenergic receptor (ADRB2) might not benefit from

25 The effect of beta2-adrenergic receptor (ADRB2) polymorphisms on the t

26 receptor target of beta-agonist therapy, the beta2-adrenergic receptor (ADRB2).

27 Sympathetic signalling via beta2-adrenergic receptors (Adrb2) present on osteoblast

28 ell-specific analysis of the function of the beta2 adrenergic receptor (Adrbeta2) and various genes i

29 enotype at the 16th aminoacid residue of the beta2-adrenergic receptor affects the long-term response

30 s alone or in combination with a long-acting beta2 -adrenergic receptor agonist (LABA) on GCM in the

31 dependent stimulation of beating rate by the beta2 adrenergic receptor agonist procaterol was signifi

32 yses revealed that formoterol, a long-acting beta2 adrenergic receptor agonist, caused significant im

33 in the rat cerebral cortex is induced by the beta2-adrenergic receptor agonist clenbuterol (CLE).

34 Here, we show that treatment with the beta2-adrenergic receptor agonist clenbuterol increases

35 Salmeterol is a long-acting beta2-adrenergic receptor agonist used to treat chronic

36 or treating airway obstructive diseases, and beta2 adrenergic receptor agonists have been the most co

37 nition in Ts65Dn mice, formoterol or similar beta2 adrenergic receptor agonists with ability to cross

38 y of commonly used asthma therapies, such as beta2-adrenergic receptor agonists (beta-agonists).

39 ing mechanism of Rett syndrome and introduce beta2-adrenergic receptor agonists as potential therapeu

40 empty G-protein binding site of an activated beta2 adrenergic receptor and form salt-bridge interacti

41 mized models incorporating the structures of beta2-adrenergic receptor and 5-HT2B receptor.

42 gamma receptor, a polymorphism marker in the beta2-adrenergic receptor and a low-inducible allele of

43 ased on the recent crystal structures of the beta2-adrenergic receptor and A2a-adenosine receptor.

44 gion of a constitutively active mutant human beta2-adrenergic receptor and attaching Renilla reniform

45 n of the LCP-Tm assay to an engineered human beta2-adrenergic receptor and bacteriorhodopsin revealed

46 Thus, signaling via the erythrocyte beta2-adrenergic receptor and Galphas may regulate malar

47 ave found that signaling via the erythrocyte beta2-adrenergic receptor and heterotrimeric guanine nuc

48 After protracted stimulation, the beta2-adrenergic receptor and many other G-protein-coupl

49 ptor b2, whereas two Rhodopsin-family GPCRs, beta2-adrenergic receptor and mCannR2, exhibit colocaliz

50 Using the beta2-adrenergic receptor and rhodopsin as receptor subs

51 structures: the adenosine A2A receptor, the beta2-adrenergic receptor and rhodopsin.

52 -binding and transmembrane segments from the beta2-adrenergic receptor and the cytoplasmic domains fr

53 y feature of the EE effect was activation of beta2-adrenergic receptors and downstream cAMP/PKA signa

54 protein (GFP)-arr3 in live cells expressing beta2-adrenergic receptors and fluorescent CL.

55 iated activation of RhoA in AEC occurred via beta2-adrenergic receptors and involved Gs-PKA as demons

56 tudies demonstrating disparate regulation of beta2-adrenergic receptors and microRNA between pediatri

57 nd epinephrine, proceeding through the beta1/beta2-adrenergic receptors and protein kinase A, resulti

58 he immunocomplex between a membrane protein, beta2 adrenergic receptor, and anti-FLAG antibody has be

59 ing the crystal structures of rhodopsin, the beta2-adrenergic receptor, and the ligand-free opsin, wh

60 ippocampal LTP, decreased neuronal levels of beta2-adrenergic receptors, and activated microglia in w

61 ), cecal peritonitis with dopexamine and the beta2-adrenergic receptor antagonist ICI 118,551 (n = 4)

62 mimicked by administration of the selective beta2-adrenergic receptor antagonist ICI-118,551.

63 Cotreatment with a beta2-adrenergic receptor antagonist, butoxamine, sugges

64 were subjected to the nonselective (beta1 + beta2) adrenergic receptor antagonists propranolol or na

65 We report the 3D structure of human beta2 adrenergic receptor (AR) predicted by using the Me

66 However, ISO response was reversed by beta2-adrenergic receptor (AR) inhibition.

67 er kidney cells, the human beta1-but not the beta2-adrenergic receptor (AR) is totally resistant to a

68 yocardial contractile response to beta1- and beta2-adrenergic receptor (AR) stimulation is severely i

69 es exist after stimulation of the beta1- and beta2-adrenergic receptor (AR) subtypes.

70 the angiotensin II type 1A receptor (AT1R), beta2-adrenergic receptor (AR), and alpha2B-AR in HEK293

71 s (BF) and heavy/non-buoyant fractions (HF); beta2-adrenergic receptors (AR) in BF; and AC5/6, beta1-

72 beta1- and beta2-adrenergic receptors (AR) regulate cardiac myocyte

73 owever, in contrast to the activation of the beta2-adrenergic receptor, arrestin was not necessary fo

74 Using the beta2-adrenergic receptor as a model, we present a proof

75 estin-3 and its 3A mutant that readily binds beta2-adrenergic receptors as well as two mutants impair

76 Real-time cAMP analysis in beta1- and beta2-adrenergic receptor-associated membrane microdomai

77 inine at the 16th amino acid position of the beta2-adrenergic receptor (B16 Arg/Arg) benefit less fro

78 tudies showed that epinephrine activates the beta2-adrenergic receptor (B2AR), impairing keratinocyte

79 The luteinizing hormone receptor (LHR) and beta2-adrenergic receptor (B2AR), two GPCRs sorted to th

80 cardiac death (SCD), mediated in part by the beta2-adrenergic receptor (B2AR).

81 One of the defining properties of beta2-adrenergic receptor (beta(2)AR) signaling is the t

82 n the tumor microenvironment is regulated by beta2-adrenergic receptor (beta-AR) signaling in host im

83 ompartmentalize cAMP signaling transduced by beta2-adrenergic receptors (beta(2)ARs); such compartmen

84 Cardiomyocyte beta2-adrenergic receptors (beta-ARs) provide a source o

85 study, we report that mice with no beta1- or beta2-adrenergic receptors (beta1AR-/-/beta2AR-/-) have

86 Recent research has revealed that beta2 -adrenergic receptor (beta2 -AR) agonists lose bro

87 nificant elevation of phosphorylation of the beta2 -adrenergic receptor (beta2 AR) at both the protei

88 Mouse and human CPCs express only beta2 adrenergic receptor (beta2-AR) in conjunction with

89 Previously, we demonstrated that beta2-adrenergic receptor (beta2-AR) activation in kerat

90 cAMP stimulated by two Gs-coupled receptors, beta2-adrenergic receptor (beta2-AR) and D1 dopamine rec

91 It is well established that the beta2-adrenergic receptor (beta2-AR) exhibits a robust l

92 This study examines the role of the beta2-adrenergic receptor (beta2-AR) in cardioprotection

93 publication of the crystal structure of the beta2-adrenergic receptor (beta2-AR) proved that G prote

94 ll phenotypic pharmacology of ligands at the beta2-adrenergic receptor (beta2-AR) stably expressed in

95 They solely express the beta2-adrenergic receptor (beta2-AR) subtype of beta-ARs

96 endent activation and internalization of the beta2-adrenergic receptor (beta2-AR), a prototypic G-pro

97 eport here that following stimulation of the beta2-adrenergic receptor (beta2-AR), a prototypical 7TM

98 phosphorylated form of the G protein-coupled beta2-adrenergic receptor (beta2-AR), have recently emer

99 pendent phosphate cotransporter (Npt2a), and beta2-adrenergic receptor (beta2-AR), through their resp

100 ribute to selective interactions between the beta2-adrenergic receptor (beta2-AR)-Galphas and V1A rec

101 itide 3-kinase (PI3K) has been implicated in beta2-adrenergic receptor (beta2-AR)/G(i)-mediated compa

102 Keratinocytes express a high level of beta2-adrenergic receptors (beta2-ARs) that appear to pl

103 o the plasma membrane upon coexpression with beta2-adrenergic receptors (beta2-ARs) through an intera

104 g bone deposition and resorption through the beta2-adrenergic receptors (beta2-ARs).

105 ssing the stimulatory G protein fused to the beta2 adrenergic receptor (beta2AR) and AC were incubate

106 ism of their activation process, as only the beta2 adrenergic receptor (beta2AR) and rhodopsin have b

107 Here we show that the rapidly recycling beta2 adrenergic receptor (beta2AR) binds via a determin

108 The role of the beta2 adrenergic receptor (beta2AR) in the regulation of

109 carboxyl-terminal cytoplasmic domain of the beta2 adrenergic receptor (beta2AR) mediates both PDZ bi

110 Engagement of the beta2 adrenergic receptor (beta2AR) on a B cell is known

111 helix 6 (Cys-265), (19)F NMR spectra of the beta2 adrenergic receptor (beta2AR) reconstituted in mal

112 (Cmpd-15) is an allosteric modulator of the beta2 adrenergic receptor (beta2AR) that was recently is

113 The beta2 adrenergic receptor (beta2AR) undergoes desensitiz

114 fer imaging, we examine TM6 movements in the beta2 adrenergic receptor (beta2AR) upon exposure to ort

115 we reconsider oligomerization of the class A beta2 adrenergic receptor (beta2AR), and reevaluate BRET

116 adenosine 2B receptor (A2BR), but not of the beta2 adrenergic receptor (beta2AR), leading to an enhan

117 ing the membrane-proximal amino acids of the beta2 adrenergic receptor (beta2AR), the sphingosine 1-p

118 uestion by comparing human Wntless (Wls) and beta2 adrenergic receptor (beta2AR), which require retro

119 We observed that in beta2 adrenergic receptor (beta2AR)-expressing HEK-293 c

120 ral data on a number of GPCRs, including the beta2 adrenergic receptor (beta2AR)-G-protein complex, h

121 vated protein (MAP) kinase activation by the beta2 adrenergic receptor (beta2AR).

122 re we show in atomistic detail how the human beta2-adrenergic receptor (beta2AR) - a prototypical G p

123 In this article, we demonstrate that beta2-adrenergic receptor (beta2AR) activation in LPS-st

124 Salmeterol is a long-acting beta2-adrenergic receptor (beta2AR) agonist that is wide

125 cle hypertrophy stimulated by clenbuterol, a beta2-adrenergic receptor (beta2AR) agonist, was signifi

126 beta2-Adrenergic receptor (beta2AR) agonists are critica

127 l and small clinical studies have shown that beta2-adrenergic receptor (beta2AR) agonists enhance AFC

128 PCL interacts with beta2-adrenergic receptor (beta2AR) and co-localizes wit

129 he model G-protein-coupled receptors (GPCRs) beta2-adrenergic receptor (beta2AR) and Mu-opioid recept

130 y we predicted the 3D structure of the human beta2-adrenergic receptor (beta2AR) and of the binding s

131 In addition to phosphorylating the beta2-adrenergic receptor (beta2AR) and other receptors,

132 -binding and transmembrane segments from the beta2-adrenergic receptor (beta2AR) and the cytoplasmic

133 observed for agonist-bound structures of the beta2-adrenergic receptor (beta2AR) and the M2 muscarini

134 Adenoviral-mediated rescue of beta2-adrenergic receptor (beta2AR) function into the al

135 nucleotide polymorphisms (SNPs) in the human beta2-adrenergic receptor (beta2AR) gene.

136 ous for arginine (ArgArg) at codon 16 of the beta2-adrenergic receptor (beta2AR) have been shown to h

137 participating in the phosphorylation of the beta2-adrenergic receptor (beta2AR) have in part been li

138 r (CB1-Gi), guided by the x-ray structure of beta2-adrenergic receptor (beta2AR) in complex with Gs (

139 noprecipitated with overexpressed TPbeta and beta2-adrenergic receptor (beta2AR) in HEK 293 cells, bu

140 rine network exists in skin, but the role of beta2-adrenergic receptor (beta2AR) in wound healing is

141 The beta2-adrenergic receptor (beta2AR) is a prototypical G

142 The beta2-adrenergic receptor (beta2AR) is a well-studied pr

143 Agonist-stimulated desensitization of the beta2-adrenergic receptor (beta2AR) is caused by both a

144 Although the beta2-adrenergic receptor (beta2AR) is the most extensiv

145 release of catecholamines, which engage the beta2-adrenergic receptor (beta2AR) on murine alveolar m

146 rine models of asthma, agonist-activation of beta2-adrenergic receptor (beta2AR) or Protease-activate

147 beta2-Adrenergic receptor (beta2AR) plays a critical rol

148 The beta2-adrenergic receptor (beta2AR) plays important phys

149 y determined crystal structures of the human beta2-adrenergic receptor (beta2AR) provide a long-await

150 Efficient recycling of the beta2-adrenergic receptor (beta2AR) requires a C-termina

151 Dietary Na+ intake influences beta2-adrenergic receptor (beta2AR) responsiveness.

152 lphas-CFP, YFP-N-beta1/YFP-C-gamma7, and the beta2-adrenergic receptor (beta2AR) resulted in internal

153 -coupled receptor kinases (GRKs) desensitize beta2-adrenergic receptor (beta2AR) signaling, and these

154 by a B cell is increased following CD86 and beta2-adrenergic receptor (beta2AR) stimulation, through

155 Here, we identify beta2-adrenergic receptor (beta2AR) that mediates Abeta-

156 al dynamics of the cytoplasmic domain of the beta2-adrenergic receptor (beta2AR) using (19)F-fluorine

157 (GRK) site phosphoserines 355 and 356 of the beta2-adrenergic receptor (beta2AR) were characterized i

158 ort the requirement of an association of the beta2-adrenergic receptor (beta2AR) with the pore formin

159 we demonstrate that a prototypical GPCR, the beta2-adrenergic receptor (beta2AR), can be incorporated

160 specific Cy3 fluorescence probe in the human beta2-adrenergic receptor (beta2AR), we observed that in

161 this study, we describe for the first time a beta2-adrenergic receptor (beta2AR)-activating monoclona

162 The suppression was prevented when a beta2-adrenergic receptor (beta2AR)-selective agonist wa

163 e ensemble of conformations sampled by human beta2-adrenergic receptor (beta2AR).

164 f Zn(2+) on the functional properties of the beta2-adrenergic receptor (beta2AR).

165 docking to analyze GRK5 interaction with the beta2-adrenergic receptor (beta2AR).

166 ARRDC3 in regulating the trafficking of the beta2-adrenergic receptor (beta2AR).

167 and stabilize an active conformation of the beta2-adrenergic receptor (beta2AR).

168 in three different conformational states of beta2-adrenergic receptor (beta2AR): 1), the inverse-ago

169 hma, the response to beta-agonists acting at beta2-adrenergic receptors (beta2AR) displays extensive

170 We find, however, that co-expression of beta2-adrenergic receptors (beta2AR) in HEK-293T routes

171 We report here that a population of human beta2-adrenergic receptors (beta2AR), a canonical G prot

172 afficking and recycling of agonist-activated beta2 adrenergic receptors (beta2ARs).

173 We previously demonstrated the importance of beta2-adrenergic receptors (beta2ARs) in the regulation

174 Agonist stimulation of the beta2-adrenergic receptors (beta2ARs) leads to their ubi

175 The beta2-adrenergic receptors (beta2ARs) play a role in ren

176 ficant population of Galphai and its coupled beta2-adrenergic receptor (betaAR), are localized to cav

177 Beta1- and beta2-adrenergic receptors (betaARs) are highly homologo

178 through adrenergic receptors (ARs), of which beta2-adrenergic receptors (betaARs) are of particular i

179 The beta1- and beta2-adrenergic receptors (betaARs) on the surface of c

180 Conversely, selective beta2 adrenergic receptor blockade did not affect MCFP r

181 ectomy, ganglionic-blocker administration or beta2-adrenergic receptor blockade.

182 beta2-Adrenergic receptor blocker treatment reduced arrh

183 Here we report on the dynamics of the beta2 adrenergic receptor bound to the beta-arrestin and

184 The structures of beta2-adrenergic receptor bound with a variety of ligand

185 Catecholamines signal through the beta2-adrenergic receptor by promoting production of the

186 -regulating genes (those encoding beta1- and beta2-adrenergic receptors, calcium ATPase in the sarcop

187 Strikingly, the beta2 adrenergic receptor can substitute for an OR in gl

188 cent high resolution x-ray structures of the beta2-adrenergic receptor confirmed a close salt-bridge

189 We found that in Src-deficient cells the beta2-adrenergic receptor could activate the MAPK pathwa

190 hosphorylation of the Tyr-350 residue of the beta2-adrenergic receptor creates a conditional, canonic

191 receptor (DOR) molecular model based on the beta2-adrenergic receptor crystal structure are explored

192 this study we have defined a sequence in the beta2-adrenergic receptor cytoplasmic tail that confers

193 In further mechanistic studies using beta2-adrenergic receptor-deficient (beta2-AR(-/-)) mice

194 nase A-dependent manner, an effect lost when beta2-adrenergic receptor-deficient B cells were used.

195 is of the delta-opioid receptor, but not the beta2-adrenergic receptor, defining a role for CLCs in t

196 Further, we demonstrate that beta2-adrenergic receptor-dependent activation of proinf

197 Importantly, phosphorylation of the inactive beta2-adrenergic receptor enhanced its interactions with

198 Time-lapse imaging of the beta2 adrenergic receptor expressed in cultured rat hipp

199 We used this microfluidic device to quantify beta2 adrenergic receptors expressed in insect cells (SF

200 xpress the beta1-adrenergic receptor with no beta2-adrenergic receptor expression observed.

201 We demonstrate the utility of beta2-adrenergic receptor-Frizzled chimeras to provide t

202 implicated in the switching of signaling of beta2-adrenergic receptors from adenylylcyclase coupling

203 orters; and 2), rhodopsin and the beta1- and beta2-adrenergic receptors from the G-protein coupled re

204 , variation in haplotype frequencies for the beta2 adrenergic receptor gene was found to be associate

205 The beta2-adrenergic receptor gene (ADRB2) contains a common

206 Variants of beta2-adrenergic receptor gene (ADRB2) have been associa

207 s important in understanding the function of beta2-adrenergic receptor gene (ADRbeta2) on disease sus

208 6 to 6.09; P=0.001; FDR, P=0.036) and a Q27E beta2-adrenergic receptor gene polymorphism (OR, 1.40; 9

209 There was no association of beta2-adrenergic receptor genotype with ischemic stroke

210 Pase exocytosis in AEC via the activation of beta2-adrenergic receptor, Gs, PKA, Gi, RhoA, and ROCK.

211 ealed an architecture similar to that of the beta2-adrenergic receptor-GS complex, including a flexib

212 FTR overexpression in mice with no beta1- or beta2-adrenergic receptors had no effect on AFC.

213 %, respectively, P = 0.003), irrespective of beta2-adrenergic receptor haplotype.

214 3%, respectively, P = 0.01), irrespective of beta2-adrenergic receptor haplotype.

215 tic polymorphisms at codons 16 and 27 of the beta2-adrenergic receptor have been associated with alte

216 active and active experimental structures of beta2 adrenergic receptor (hbeta2AR) and M2 muscarinic a

217 We conclude that beta1- and beta2-adrenergic receptor homodimers with TM1/H8 at the

218 ere consistent with the crystal structure of beta2 adrenergic receptor in complex with Gs Conformatio

219 a molecule that is rapidly recruited to the beta2-adrenergic receptor in a beta-arrestin1-dependent

220 s simulations to explore dimerization of the beta2-adrenergic receptor in lipid bilayers containing c

221 Colocalization of CB1 and beta2-adrenergic receptors in the oviduct muscularis imp

222 th processes by recruiting PDEs to activated beta2-adrenergic receptors in the plasma membrane of mam

223 sing a model G protein-coupled receptor, the beta2-adrenergic receptor, including experiments that ch

224 Also, the beta2-adrenergic receptor-induced increase in the level

225 and beta-arrestin 2 play essential roles in beta2-adrenergic receptor internalization, they are not

226 n with mu-adaptin and the ability to enhance beta2-adrenergic receptor internalization.

227 Our data suggest that targeting beta2 adrenergic receptors is an effective strategy for

228 The beta2-adrenergic receptor is an important member of the

229 The Arg16 polymorphism of the beta2-adrenergic receptor is associated with enhanced ag

230 the prototypical G protein-coupled receptor beta2-adrenergic receptor is partially preassociated in

231 Although the location of carazolol in the beta2-adrenergic receptor is very similar to that of ret

232 of endothelial Adrb2, the gene encoding the beta2-adrenergic receptor, leads to inhibition of angiog

233 found that downregulation of Rnd3 attenuated beta2-adrenergic receptor lysosomal targeting and ubiqui

234 ous for arginine at the 16th position of the beta2-adrenergic receptor may not benefit from short-act

235 a critical role for C/EBPdelta in regulating beta2-adrenergic receptor-mediated NGF expression in viv

236 of hippocampal synaptic plasticity including beta2-adrenergic receptor-mediated plasticity, and selec

237 t muscularis and norepinephrine signaling to beta2 adrenergic receptors on MMs.

238 of CD86 (formerly known as B7-2) and/or the beta2-adrenergic receptor on a CD40 ligand/interleukin-4

239 e effects of two common polymorphisms of the beta2-adrenergic receptor, one at codon 16 and one at co

240 Here we show that a chimeric rhodopsin/beta2 adrenergic receptor (opto-beta2AR) is similar in d

241 meric receptor composed of rhodopsin and the beta2-adrenergic receptor (Opto-beta2AR) with in vivo op

242 MRAP did not alter expression of beta2-adrenergic receptors or co-precipitate with them.

243 evealed that recruitment of arrestin3 to the beta2-adrenergic receptor orchestrates the sequestration

244 tural analysis of two other GPCRs, beta1 and beta2 adrenergic receptors, our results could reveal a g

245 act ventricular myocytes via both beta1- and beta2-adrenergic receptor pathways, but the beta2-depend

246 ch is associated with significant changes in beta2 -adrenergic receptor phosphorylation at protein ki

247 Furthermore, both hippocampal beta2-adrenergic receptor phosphorylation by PKA, and le

248 sis in prostate cancer cells via epinephrine/beta2 adrenergic receptor/PKA/BAD pathway.

249 Blockade of alpha1/alpha2- and beta1/beta2-adrenergic receptors prevented the stress-induced

250 anglionectomy or pharmacological blockade of beta2-adrenergic receptors prevents NPPE release into th

251 ne rhodopsin and the recently released human beta2 adrenergic receptor protein structure.

252 , which in turn resulted in the elevation of beta2-adrenergic receptor protein levels leading to the

253 ent high-resolution crystal structure of the beta2-adrenergic receptor revealed the presence of possi

254 the signaling profiles of 28 variants of the beta2-adrenergic receptor reveals three clearly distinct

255 tes is able to normalize the distribution of beta2 adrenergic receptor signal by preventing PKA signa

256 n the myofilaments is because of an enhanced beta2 adrenergic receptor signal selectively directed to

257 We further demonstrate that the endosomal beta2-adrenergic receptor signal confers uniformity on t

258 ntroduction of caveolin-3 is able to confine beta2 adrenergic receptor signaling and restore myocyte

259 rophic rabbit myocytes, selectively enhanced beta2 adrenergic receptor signaling toward the myofilame

260 pool of PKA that regulates learning-induced beta2-adrenergic receptor signaling and ERK activation i

261 rosine kinases to examine the role of Src in beta2-adrenergic receptor signaling to the MAPK pathway

262 receptor internalization is not required for beta2-adrenergic receptor signaling to the MAPK pathway

263 h high-fat diet (HFD) feeding on the cardiac beta2 -adrenergic receptor signalling and the impacts on

264 Beta2-adrenergic receptor stimulation increased CREB pho

265 is effect, we determined whether CD86 and/or beta2-adrenergic receptor stimulation regulated transcri

266 C- and NF-kappaB1-dependent manner, and that beta2-adrenergic receptor stimulation up-regulates the e

267 haracterized a homogeneous population of the beta2 adrenergic receptor subtype expressed on these cel

268 We report the crystal structure of a human beta2-adrenergic receptor-T4 lysozyme fusion protein bou

269 -AR chimera containing the type I PDZ of the beta2-adrenergic receptor that does not bind to SAP97 fa

270 enhanced affinity for the agonist-activated beta2-adrenergic receptor that traffics into endocytic v

271 GE(2) by > 50%; (ii) had no effect on EP4 or beta2 adrenergic receptors, the cAMP assay itself, or th

272 eral G protein-coupled receptors such as the beta2-adrenergic receptor, the kappa-opioid receptor, an

273 Cav1.2 forms a complex with the beta2-adrenergic receptor, the trimeric GS protein, aden

274 In the case of the beta2 adrenergic receptor, these ligands are generally s

275 eceptors at the plasma membrane, such as the beta2 adrenergic receptor, they remain associated with o

276 ine Ca2+ influx, and can be modulated by the beta2 adrenergic receptor through PKA in a highly compar

277 of ligands and investigated their impacts on beta2-adrenergic receptor through a total of 12 x 100 ns

278 Control studies established that the beta2-adrenergic receptor TM VI peptide that disrupts ol

279 thereby explaining failure of the wild type beta2-adrenergic receptor to recycle efficiently by defa

280 ol-sensitive AFC in mice with beta1- but not beta2-adrenergic receptors to beta1AR-/-/beta2AR-/- mice

281 A beta2-adrenergic receptor truncated distal to residue 38

282 by a mechanism that attenuates Rnd3-mediated beta2-adrenergic receptor ubiquitination, which leads to

283 ity to map the oligomerization energy of the beta2-adrenergic receptor using approximately 10(9)-fold

284 The Glu27 allele of the beta2-adrenergic receptor was associated with a lower ri

285 n beta-arrestin 2 the internalization of the beta2-adrenergic receptor was impaired, whereas the acti

286 as the activation of the MAPK pathway by the beta2-adrenergic receptor was normal.

287 In HEK 293 cells, the G(s)-coupled beta2-adrenergic receptor was postulated to initiate a s

288 However, the internalization of beta2-adrenergic receptors was blocked in Src-deficient

289 g data for a set of small molecules with the beta2 adrenergic receptor, we demonstrate that deconvolu

290 Starting from the crystal structure of the beta2-adrenergic receptor, we have used coarse grain com

291 for homomers of the cognate human beta1- and beta2-adrenergic receptors, we have carried out approxim

292 rged amino acids in the proximal tail of the beta2-adrenergic receptor were also important for GRK-de

293 edema formation in sepsis by stimulation of beta2-adrenergic receptors, whereas the alpha1 adrenocep

294 l of ERK2 more efficiently than alpha 1b and beta2 adrenergic receptors, which form transient recepto

295 We observed that the content of beta2-adrenergic receptors, which are mainly expressed i

296 Activation of beta2 adrenergic receptors with salbutamol (40 microm) o

297 racellular and transmembrane portions of the beta2-adrenergic receptor with cytoplasmic domains of Rf

298 Mutant beta2-adrenergic receptors with a Tyr-to-Phe substitutio

299 was inhibited by blockade of the beta1- and beta2-adrenergic receptors with propranolol, and by bloc

300 eviously to be required for recycling of the beta2 adrenergic receptor yet is functionally interchang